Showing 6811-6820 of 8579 results for "".
- Positive Results Seen in Phase 3 FMX101 Acne Studyhttps://practicaldermatology.com/news/study-positive-results-see-in-phase-3-fmx101-acne-study/2460088/In patients with moderate to severe acne vulgaris, treatment with FMX101 4% topical minocycline foam is well tolerated and effective for reducing the number of inflammatory lesions, according to results of a randomized trial published in the Journal of the American Academy of Dermatology
- AARS Survey Uncovers Real Impact Of Acne On Young Professionalshttps://practicaldermatology.com/news/aars-survey-uncovers-real-impact-of-acne-on-young-professionals/2460087/Results of a recent American Acne and Rosacea Society (AARS) survey highlight the significant health burden and everyday impact of acne on young professionals. According to the survey of 1,004 men and women between the ages of 22 and 30 conducted by The Harris Poll, many people whose acne persist
- Hair Loss Breakthrough: 3D-Printing Creates “Hair Farms”https://practicaldermatology.com/news/hair-loss-breakthrough-research-uses-3d-printing-to-create-hair-farms/2460083/Columbia researchers have created a way to use 3-D printing to create “hair farms” in a dish, which could open up hair restoration surgery to more people, including women, and improve the way pharmaceutical companies search for new hair growth drugs. The findings, which appe
- BioPharmX’s BPX-04 Performs Well in Rosacea Trialhttps://practicaldermatology.com/news/biopharmxs-bpx-04-performs-well-in-rosacea-trial/2460078/BioPharmX Corporation ‘s BPX-04, a novel topical gel formulation of fully solubilized minocycline for the treatment of moderate-to-severe papulopustular rosacea, performed well in a Phase 2b clinical trial, the Company reports. In the trial,
- FDA Clears Allergan's CoolTone Devicehttps://practicaldermatology.com/news/fda-clears-allergans-cooltone-device/2460075/The FDA has cleared Allergan plc's CoolTone device for improvement of abdominal tone, strengthening of the abdominal muscles, and development for firmer abdomen. CoolTone is also indicated for strengthening, toning and firming of buttocks and thighs. “By partnering with A
- New Data Support Clinical Utility of DermTech's PLAhttps://practicaldermatology.com/news/new-data-support-clinical-utility-of-dermtechs-pla/2460074/A new clinical study confirms the clinical utility of the DermTech’s pigmented lesion assay (PLA)in the early detection of melanoma. The PLA is a non-invasive test that uses molecular gene expression to identify malignant changes in a skin sample collected with adhesive
- Proactiv Works to Change the Conversation about Acne with New Initiativeshttps://practicaldermatology.com/news/proactiv-works-to-change-the-conversation-about-acne-with-new-initiatives/2460072/Proactiv is taking on the acne positivity movement with new initiatives aimed to help validate the emotional journey of people with acne and inspire compassion for others. As part of these initiatives, Brand Ambassador Kendall Jenner will continue
- Joanna Zucker is New CEO at PCA Skinhttps://practicaldermatology.com/news/joanna-zucker-is-new-ceo-at-pca-skin/2460071/With more than 25 years of experience in Consumer Packaged Goods and Retail, Joanna Zucker is assuming the role of Chief Executive Officer for PCA SKIN, part of Colgate-Palmolive's professional skin care portfolio. Ms. Zucker previously served in senior management and marketing
- Sonrei Sea Clearly Gel Sunscreens Launchhttps://practicaldermatology.com/news/sonrei-sea-clearly-gel-sunscreens-launch/2460070/A new eco-friendly, gel-based sunscreen line from Sonrei, LLC is now available. “Crafted for every kind,” Sonrei is driven by a commitment of bringing to market a translucent broad-spectrum SPF with environmental principles at the core, the company says. Sonrei Sea Clearly T
- Lilly: Taltz Tops Adalimumab for PsA in Head-to-Headhttps://practicaldermatology.com/news/lilly-taltz-tops-adalimumab-for-psa-in-head-to-head/2460069/Results of the phase 3b/4 SPIRIT-Head-to-Head (H2H) study in patients with active psoriatic arthritis (PsA), presented as a late-breaking abstract at the European Congress of Rheumatology (EULAR) in Madrid, show that a significantly higher proportion of patients met the primary end